Palle Bekker Jeppesen

List of Publications by Year
in descending order

138	8,759	50244 46	43868 91
papers	citations	h-index	g-index

139	139	139	3565
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ESPEN guidelines on chronic intestinal failure in adults. Clinical Nutrition, 2016, 35, 247-307.	2.3	554
2	Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology, 2001, 120, 806-815.	0.6	490
3	ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clinical Nutrition, 2015, 34, 171-180.	2.3	473
4	Short Bowel Syndrome and Intestinal Failure: Consensus Definitions and Overview. Clinical Gastroenterology and Hepatology, 2006, 4, 6-10.	2.4	440
5	Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut, 2005, 54, 1224-1231.	6.1	403
6	Teduglutide Reduces Need for Parenteral Support Among Patients With Short Bowel Syndrome With Intestinal Failure. Gastroenterology, 2012, 143, 1473-1481.e3.	0.6	378
7	ESPEN Guidelines on Parenteral Nutrition: Home Parenteral Nutrition (HPN) in adult patients. Clinical Nutrition, 2009, 28, 467-479.	2.3	365
8	Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut, 2011, 60, 902-914.	6.1	345
9	The influence of a preserved colon on the absorption of medium chain fat in patients with small bowel resection. Gut, 1998, 43, 478-483.	6.1	192
10	Quality of life in patients receiving home parenteral nutrition. Gut, 1999, 44, 844-852.	6.1	189
11	Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut, 2000, 47, 370-376.	6.1	176
12	Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Gut, 2000, 47, 199-205.	6.1	173
13	Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome. Clinical and Translational Gastroenterology, 2016, 7, e142.	1.3	155
14	Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut, 1999, 45, 559-563.	6.1	149
15	Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection. Gut, 1998, 43, 763-769.	6.1	142
16	Intestinal failure defined by measurements of intestinal energy and wet weight absorption. Gut, 2000, 46, 701-706.	6.1	141
17	Safety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Intestinal Failure. Clinical Gastroenterology and Hepatology, 2013, 11, 815-823.e3.	2.4	135
18	Spectrum of Short Bowel Syndrome in Adults. Journal of Parenteral and Enteral Nutrition, 2014, 38, 8S-13S.	1.3	130

#	Article	IF	Citations
19	In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2884-2888.	1.8	126
20	In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2884-2888.	1.8	124
21	ESPEN Guidelines on Parenteral Nutrition: Gastroenterology. Clinical Nutrition, 2009, 28, 415-427.	2.3	119
22	Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. Gastroenterology, 2018, 154, 874-885.	0.6	92
23	Short-term Administration of Glucagon-like Peptide-2. Effects on Bone Mineral Density and Markers of Bone Turnover in Short-Bowel Patients with No Colon. Scandinavian Journal of Gastroenterology, 2002, 37, 392-398.	0.6	91
24	Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Therapeutic Advances in Gastroenterology, 2012, 5, 159-171.	1.4	81
25	Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide â€“ Analyses from a randomised, placebo-controlled study. Clinical Nutrition, 2013, 32, 713-721.	2.3	80
26	Colonic Digestion and Absorption of Energy From Carbohydrates and Mediumâ€Chain Fat in Small Bowel Failure. Journal of Parenteral and Enteral Nutrition, 1999, 23, S101-5.	1.3	77
27	The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regulatory Peptides, 2011, 168, 32-38.	1.9	77
28	Home parenteral nutrition in Denmark in the period from 1996 to 2001. Scandinavian Journal of Gastroenterology, 2006, 41, 401-407.	0.6	74
29	ESPEN practical guideline: Clinical nutrition in chronic intestinal failure. Clinical Nutrition, 2021, 40, 5196-5220.	2.3	74
30	The truncated metabolite GLP-2 (3â€“33) interacts with the GLP-2 receptor as a partial agonist. Regulatory Peptides, 2002, 103, 9-15.	1.9	73
31	Essential fatty acid deficiency in patients receiving home parenteral nutrition. American Journal of Clinical Nutrition, 1998, 68, 126-133.	2.2	71
32	Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study. Regulatory Peptides, 2013, 184, 30-39.	1.9	69
33	Essential fatty acid deficiency in patients with severe fat malabsorption. American Journal of Clinical Nutrition, 1997, 65, 837-843.	2.2	67
34	Bile Acid Replacement Therapy with Cholylsarcosine for Short-Bowel Syndrome. Scandinavian Journal of Gastroenterology, 1999, 34, 818-823.	0.6	64
35	Effect of High-Dose Growth Hormone and Glutamine on Body Composition, Urine Creatinine Excretion, Fatty Acid Absorption, and Essential Fatty Acids Status in Short Bowel Patients. A Randomized, Double-blind, Crossover, Placebo-controlled Study. Scandinavian Journal of Gastroenterology, 2001, 36, 48-54.	0.6	63
36	Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resection. Gut, 2003, 52, 653-658.	6.1	63

#	Article	IF	Citations
37	Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome. Journal of Parenteral and Enteral Nutrition, 2017, 41, 946-951.	1.3	62
38	Gut hormones in the treatment of short-bowel syndrome and intestinal failure. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 14-20.	1.2	60
39	Intestinal growth adaptation and glucagon-like peptide 2 in rats with ileal–jejunal transposition or small bowel resection. Digestive Diseases and Sciences, 2001, 46, 379-388.	1.1	57
40	Pharmacologic Options for Intestinal Rehabilitation in Patients With Short Bowel Syndrome. Journal of Parenteral and Enteral Nutrition, 2014, 38, 45S-52S.	1.3	55
41	Home Parenteral Nutrition in Adult Patients With Chronic Intestinal Failure: The Evolution Over 4 Decades in a Tertiary Referral Center. Journal of Parenteral and Enteral Nutrition, 2017, 41, 1178-1187.	1.3	55
42	Adult Patients Receiving Home Parenteral Nutrition in Denmark from 1991 to 1996: Who Will Benefit from Intestinal Transplantation?. Scandinavian Journal of Gastroenterology, 1998, 33, 839-846.	0.6	54
43	Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial. American Journal of Clinical Nutrition, 2017, 106, 839-848.	2.2	53
44	Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 354-363.	3.7	52
45	Deficiencies of essential fatty acids, vitamin A and E and changes in plasma lipoproteins in patients with reduced fat absorption or intestinal failure. European Journal of Clinical Nutrition, 2000, 54, 632-642.	1.3	51
46	Glucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates. American Journal of Physiology - Renal Physiology, 2013, 305, G277-G285.	1.6	48
47	Effect of Liraglutide Treatment on Jejunostomy Output in Patients With Short Bowel Syndrome: An Openâ€Łabel Pilot Study. Journal of Parenteral and Enteral Nutrition, 2018, 42, 112-121.	1.3	48
48	Short Bowel Syndrome in Adults. Journal of Parenteral and Enteral Nutrition, 2014, 38, 60S-64S.	1.3	47
49	Development and validation of the disease-specific Short Bowel Syndrome-Quality of Life (SBS-QoLâ„¢) scale. Clinical Nutrition, 2013, 32, 789-796.	2.3	45
50	Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition. Alimentary Pharmacology and Therapeutics, 2018, 48, 410-422.	1.9	45
51	Enhancing bowel adaptation in short bowel syndrome. Current Gastroenterology Reports, 2002, 4, 338-347.	1.1	44
52	Glucagon-Like Peptide-2: Update of the Recent Clinical Trials. Gastroenterology, 2006, 130, S127-S131.	0.6	44
53	European Society of Coloproctology consensus on the surgical management of intestinal failure in adults. Colorectal Disease, 2016, 18, 535-548.	0.7	44
54	Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scandinavian Journal of Gastroenterology, 2008, 43, 1304-1310.	0.6	39

#	Article	IF	Citations
55	Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure. Journal of Parenteral and Enteral Nutrition, 2020, 44, 119-128.	1.3	38
56	Differences in essential fatty acid requirements by enteral and parenteral routes of administration in patients with fat malabsorption. American Journal of Clinical Nutrition, 1999, 70, 78-84.	2.2	37
57	Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate. Scandinavian Journal of Gastroenterology, 2007, 42, 814-820.	0.6	37
58	Acute Effects of the Glucagonâ€Like Peptide 2 Analogue, Teduglutide, on Intestinal Adaptation in Short Bowel Syndrome. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 694-702.	0.9	36
59	Home Parenteral Nutrition in Adult Patients With Chronic Intestinal Failure: Catheterâ€Related Complications Over 4 Decades at the Main Danish Tertiary Referral Center. Journal of Parenteral and Enteral Nutrition, 2018, 42, 95-103.	1.3	36
60	Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected 125I-GLP-2. Peptides, 2000, 21, 1511-1517.	1.2	33
61	Novel Longâ€Acting GLPâ€2 Analogue, FE 203799 (Apraglutide), Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum. Journal of Parenteral and Enteral Nutrition, 2019, 43, 891-898.	1.3	33
62	Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. Scandinavian Journal of Gastroenterology, 2008, 43, 929-937.	0.6	32
63	New approaches to the treatments of short bowel syndrome-associated intestinal failure. Current Opinion in Gastroenterology, 2014, 30, 182-188.	1.0	32
64	Bovine Colostrum to Children With Short Bowel Syndrome. Journal of Parenteral and Enteral Nutrition, 2014, 38, 99-106.	1.3	32
65	The endogenous preproglucagon system is not essential for gut growth homeostasis in mice. Molecular Metabolism, 2017, 6, 681-692.	3.0	31
66	Pharmacokinetics of trefoil peptides and their stability in gastrointestinal contents. Peptides, 2007, 28, 1197-1206.	1.2	30
67	Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice. Physiology and Behavior, 2018, 192, 72-81.	1.0	30
68	Randomised controlled trial of colostrum to improve intestinal function in patients with short bowel syndrome. European Journal of Clinical Nutrition, 2012, 66, 1059-1065.	1.3	29
69	Catheterâ€Related Bloodstream Infections in Adults Receiving Home Parenteral Nutrition: Substantial Differences in Incidence Comparing a Strict Microbiological to a Clinically Based Diagnosis. Journal of Parenteral and Enteral Nutrition, 2018, 42, 393-402.	1.3	29
70	Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure. Regulatory Peptides, 2013, 181, 4-8.	1.9	28
71	Singleâ€Center, Adult Chronic Intestinal Failure Cohort Analyzed According to the ESPENâ€Endorsed Recommendations, Definitions, and Classifications. Journal of Parenteral and Enteral Nutrition, 2017, 41, 566-574.	1.3	28
72	Glucagon like peptide-2 and neoplasia; a systematic review. Expert Review of Gastroenterology and Hepatology, 2018, 12, 257-264.	1.4	28

#	Article	IF	Citations
73	Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482090576.	1.4	28
74	Short bowel syndrome â€“ characterisation of an orphan condition with many phenotypes. Expert Opinion on Orphan Drugs, 2013, 1, 515-525.	0.5	27
75	Catheter-related bloodstream infections in patients with intestinal failure receiving home parenteral support: risks related to a catheter-salvage strategy. American Journal of Clinical Nutrition, 2018, 107, 743-753.	2.2	26
76	The Long Road to the Development of Effective Therapies for the Short Gut Syndrome: A Personal Perspective. Digestive Diseases and Sciences, 2019, 64, 2717-2735.	1.1	26
77	Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials. Journal of Parenteral and Enteral Nutrition, 2020, 44, 697-702.	1.3	26
78	Butyrate absorption and lactate secretion in ulcerative colitis. Diseases of the Colon and Rectum, 1995, 38, 519-525.	0.7	25
79	Plasma phospholipid fatty acid pattern in severe liver disease. Journal of Hepatology, 2000, 32, 481-487.	1.8	25
80	Glucagon-like peptide-2 stimulates mucosal microcirculation measured by laser Doppler flowmetry in end-jejunostomy short bowel syndrome patients. Regulatory Peptides, 2013, 180, 12-16.	1.9	24
81	Effect of Glepaglutide, a Longâ€Acting Glucagonâ€Like Peptideâ€2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial. Journal of Parenteral and Enteral Nutrition, 2020, 44, 1535-1544.	1.3	24
82	Apraglutide, a novel glucagonâ€like peptideâ€2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placeboâ€controlled, randomized phase 2 trial. Journal of Parenteral and Enteral Nutrition, 2022, 46, 896-904.	1.3	24
83	Absorption of calcium and magnesium in patients with intestinal resections treated with medium chain fatty acids. Gut, 2000, 46, 819-823.	6.1	23
84	Growth Factors in Short-Bowel Syndrome Patients. Gastroenterology Clinics of North America, 2007, 36, 109-121.	1.0	21
85	Characteristics of adult patients with chronic intestinal failure due to short bowel syndrome: An international multicenter survey. Clinical Nutrition ESPEN, 2021, 45, 433-441.	0.5	21
86	Low-Fat, High-Carbohydrate Parenteral Nutrition (PN) May Potentially Reverse Liver Disease in Long-Term PN-Dependent Infants. Digestive Diseases and Sciences, 2015, 60, 252-259.	1.1	20
87	High Parenteral Support Volume Is Associated With Reduced Quality of Life Determined by the Shortâ€Bowel Syndrome Quality of Life Scale in Nonmalignant Intestinal Failure Patients. Journal of Parenteral and Enteral Nutrition, 2021, 45, 926-932.	1.3	20
88	GLP-1 and Intestinal Diseases. Biomedicines, 2021, 9, 383.	1.4	20
89	Experimental approaches: dietary and hormone therapy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 1041-1054.	1.0	19
90	Treatment of adult short bowel syndrome patients with teduglutide. Expert Opinion on Pharmacotherapy, 2012, 13, 235-243.	0.9	19

#	Article	IF	Citations
91	Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial. EBioMedicine, 2019, 46, 444-451.	2.7	19
92	Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series. Clinical Nutrition, 2020, 39, 1774-1777.	2.3	19
93	Modern treatment of short bowel syndrome. Current Opinion in Clinical Nutrition and Metabolic Care, 2013, 16, 1.	1.3	16
94	Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily. Leukemia and Lymphoma, 2011, 52, 400-408.	0.6	15
95	Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1267-1277.	0.9	15
96	Citrulline correlations in short bowel syndromeâ€“intestinal failure by patient stratification: Analysis of 24Âweeks of teduglutide treatment from a randomized controlled study. Clinical Nutrition, 2020, 39, 2479-2486.	2.3	14
97	Impact on caregivers of adult patients receiving parenteral support for shortâ€bowel syndrome with intestinal failure: A multinational, crossâ€sectional survey. Journal of Parenteral and Enteral Nutrition, 2022, 46, 905-914.	1.3	14
98	Nutritional Therapy in Adult Short Bowel Syndrome Patients with Chronic Intestinal Failure. Gastroenterology Clinics of North America, 2018, 47, 61-75.	1.0	13
99	Etiology and Epidemiology of Catheter Related Bloodstream Infections in Patients Receiving Home Parenteral Nutrition in a Gastromedical Center at a Tertiary Hospital in Denmark. Open Microbiology Journal, 2012, 6, 98-101.	0.2	13
100	Human Rectal Absorption of Short- and Medium-chain C2-C10Fatty Acids. Scandinavian Journal of Gastroenterology, 1998, 33, 590-594.	0.6	12
101	The Use of Hormonal Growth Factors in the Treatment of Patients with Short-Bowel Syndrome. Drugs, 2006, 66, 581-589.	4.9	12
102	Differences in methodology impact estimates of survival and dependence on home parenteral support of patients with nonmalignant short bowel syndrome. American Journal of Clinical Nutrition, 2020, 111, 161-169.	2.2	11
103	Fasting and Postprandial Plasma Citrulline and the Correlation to Intestinal Function Evaluated by 72â€Hour Metabolic Balance Studies in Short Bowel Jejunostomy Patients With Intestinal Failure. Journal of Parenteral and Enteral Nutrition, 2018, 42, 418-426.	1.3	10
104	The effect of glucagonâ€like peptideâ€1 and glucagonâ€like peptideâ€2 on microcirculation: A systematic review. Microcirculation, 2019, 26, e12367.	1.0	10
105	Hospitalizations in Patients With Nonmalignant Shortâ€Bowel Syndrome Receiving Home Parenteral Support. Nutrition in Clinical Practice, 2020, 35, 894-902.	1.1	10
106	The non-surgical treatment of adult patients with short bowel syndrome. Expert Opinion on Orphan Drugs, 2013, 1, 527-538.	0.5	9
107	Impact of intestinal failure and parenteral support on adult patients with shortâ€bowel syndrome: A multinational, noninterventional, crossâ€sectional survey. Journal of Parenteral and Enteral Nutrition, 2022, 46, 1650-1659.	1.3	9
108	Apraglutide, a novel onceâ€weekly glucagonâ€like peptideâ€2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An openâ€label phase 1 and 2 metabolic balance trial. Journal of Parenteral and Enteral Nutrition, 2022, 46, 1639-1649.	1.3	9

#	Article	IF	Citations
109	Minimal Enteral Nutrition to Improve Adaptation After Intestinal Resection in Piglets and Infants. Journal of Parenteral and Enteral Nutrition, 2018, 42, 446-454.	1.3	8
110	Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study. BMJ Open Gastroenterology, 2021, 8, e000604.	1.1	8
111	Bovine Milk-Derived Emulsifiers Increase Triglyceride Absorption in Newborn Formula-Fed Pigs. Nutrients, 2021, 13, 410.	1.7	8
112	A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients. Regulatory Peptides, 2013, 184, 47-53.	1.9	7
113	The use of metabolic balance studies in the objective discrimination between intestinal insufficiency and intestinal failure. American Journal of Clinical Nutrition, 2017, 106, ajcn158386.	2.2	7
114	Bile acidâ€“farnesoid X receptorâ€“fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial. Journal of Parenteral and Enteral Nutrition, 2022, 46, 923-935.	1.3	6
115	Mo1179 The Evolution of Treatment of Patients With Intestinal Failure With Home Parenteral Nutrition. Gastroenterology, 2012, 142, S-613-S-614.	0.6	5
116	940 Complete Enteral Autonomy and Independence From Parenteral Nutrition/Intravenous Support in Short Bowel Syndrome With Intestinal Failure - Accruing Experience With Teduglutide. Gastroenterology, 2013, 144, S-169.	0.6	5
117	Understanding incretins. Intensive Care Medicine, 2014, 40, 1751-1754.	3.9	5
118	A multi-national survey of experience and attitudes towards commencing home parenteral nutrition for patients with advanced cancer. Clinical Nutrition ESPEN, 2022, 47, 246-251.	0.5	5
119	Effects of glepaglutide, a longâ€acting glucagonâ€like peptideâ€2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phase 2 trial.. Journal of Parenteral and Enteral Nutrition, 2022, , .	1.3	5
120	Survival in patients initiating home parenteral support due to nonmalignant short bowel syndrome compared with background population. Clinical Nutrition ESPEN, 2022, 50, 170-177.	0.5	5
121	Repeated Metabolic Balance Studies in Patients With Short Bowel Syndrome. Journal of Parenteral and Enteral Nutrition, 2020, 44, 677-687.	1.3	4
122	Reply to KC McCowen, PR Ling, and BR Bistrian. American Journal of Clinical Nutrition, 2000, 71, 1008-1009.	2.2	3
123	The novel use of peptide analogs in short bowel syndrome. Expert Review of Gastroenterology and Hepatology, 2013, 7, 197-199.	1.4	3
124	Clinical nutrition in the hepatogastroenterology curriculum. World Journal of Gastroenterology, 2016, 22, 1729.	1.4	3
125	Mo2121 Catheter-Related Bloodstream Infections (CRBSIs) in Adults Intestinal Failure (IF) Patients Depending on Home Parenteral Nutrition (HPN) in a Referral Centre. Gastroenterology, 2013, 144, S-748.	0.6	2
126	Serum carotenoids and macular pigment optical density in patients with intestinal resections and healthy subjects: an exploratory study. Journal of Nutritional Science, 2018, 7, e8.	0.7	2

#	Article	IF	Citations
127	Renal function in patients with intestinal failure receiving home parenteral support. Journal of Parenteral and Enteral Nutrition, 2021, , .	1.3	2
128	Discovery of Urinary Biomarkers of Spinach Consumption Using Untargeted LCâ€MS Metabolomics in a Human Intervention Trial. Molecular Nutrition and Food Research, 2022, 66, e2100260.	1.5	2
129	Intestinal insufficiency and failure. Danish Medical Bulletin, 2003, 50, 238-61.	0.1	2
130	Reply to M Esteve-Comas and MA Gassull. American Journal of Clinical Nutrition, 2001, 73, 662.	2.2	1
131	Su2095 Survival and Cause-Specific Mortality in an Intestinal Failure Cohort Depending on Home Parenteral Nutrition (HPN) in a Referral Centre From 1970 to 2010. Gastroenterology, 2014, 146, S-544-S-545.	0.6	1
132	Su2010 â€“ Mortality and Outcomes in Patients with Non-Malignant Short Bowel Syndrome Receiving Home Parenteral Support. Gastroenterology, 2019, 156, S-689.	0.6	1
133	Reply to AL Buchman. American Journal of Clinical Nutrition, 2018, 108, 1155-1156.	2.2	0
134	Quality of Life in Diffuse Large B-Cell Lymphoma Patients Treated with CHOP-14 Based Chemotherapy Is Only Affected Temporarily. Blood, 2008, 112, 2384-2384.	0.6	0
135	Use of Teduglutide to Reduce Parenteral Support in Short Bowel Syndrome. , 2014, , 1-17.		0
136	Use of Teduglutide to Reduce Parenteral Support in Short Bowel Syndrome. , 2015, , 1913-1927.		0
137	Short Bowel Syndrome: Pharmacological Improvement of Bowel Function and Adaptation. , 2016, , 79-96.		0
138	Drug use in patients with short bowel syndrome and intestinal failure.. Danish Medical Journal, 2022, 69, .	0.5	0